tiprankstipranks
Advertisement
Advertisement

HK:2616 Stock Latest News

CStone’s CS5001 Trial Pause: What the Early Cancer Study Update Means for Investors
Company AnnouncementsCStone’s CS5001 Trial Pause: What the Early Cancer Study Update Means for Investors
2d ago
2616
CStone Gains Rapid China IND Approval for EGFR/HER3 ADC CS5007
PremiumCompany Announcements
CStone Gains Rapid China IND Approval for EGFR/HER3 ADC CS5007
2d ago
2616
CStone Pharmaceuticals Sets Board Meeting to Review Interim Results and Consider Dividend
PremiumCompany Announcements
CStone Pharmaceuticals Sets Board Meeting to Review Interim Results and Consider Dividend
17d ago
2616
CStone Management Boosts Shareholdings as Key Immuno-Oncology Asset Advances
PremiumCompany Announcements
CStone Management Boosts Shareholdings as Key Immuno-Oncology Asset Advances
1M ago
2616
CStone’s Trispecific Cancer Antibody CS2009 Secures Dual Rapid Oral Slots at ESMO 2026
PremiumCompany Announcements
CStone’s Trispecific Cancer Antibody CS2009 Secures Dual Rapid Oral Slots at ESMO 2026
1M ago
2616
CStone Strikes Oceania Deal with Arrotex for Cancer Drug Sugemalimab
PremiumCompany AnnouncementsCStone Strikes Oceania Deal with Arrotex for Cancer Drug Sugemalimab
2M ago
2616
CStone Shareholders Approve All AGM Resolutions, Renew Capital Mandates and CEO Equity Awards
Premium
Company Announcements
CStone Shareholders Approve All AGM Resolutions, Renew Capital Mandates and CEO Equity Awards
2M ago
2616
CStone’s New EGFR–HER3 Drug CS5007 Enters First-in-Human Testing: What Investors Should Know
Premium
Company Announcements
CStone’s New EGFR–HER3 Drug CS5007 Enters First-in-Human Testing: What Investors Should Know
2M ago
2616
CStone Seeks Independent Shareholder Approval for CEO Equity Awards
PremiumCompany Announcements
CStone Seeks Independent Shareholder Approval for CEO Equity Awards
2M ago
2616
CStone Launches Global Phase I Trial for New EGFR/HER3 Bispecific ADC
PremiumCompany Announcements
CStone Launches Global Phase I Trial for New EGFR/HER3 Bispecific ADC
2M ago
2616
CStone Executives Launch Joint Share Purchase Plan to Signal Confidence in Pipeline
PremiumCompany Announcements
CStone Executives Launch Joint Share Purchase Plan to Signal Confidence in Pipeline
3M ago
2616
CStone Sets 2026 AGM to Renew Board, Auditor and Share Issuance Mandate
PremiumCompany Announcements
CStone Sets 2026 AGM to Renew Board, Auditor and Share Issuance Mandate
3M ago
2616
CStone’s CS2009 Posts Strong ASCO Data as Company Prepares Global Phase III Trial
PremiumCompany AnnouncementsCStone’s CS2009 Posts Strong ASCO Data as Company Prepares Global Phase III Trial
3M ago
2616
CStone Pharmaceuticals Unveils Share Buyback Plan After Key Oncology Data Milestone
Premium
Company Announcements
CStone Pharmaceuticals Unveils Share Buyback Plan After Key Oncology Data Milestone
3M ago
2616
CStone Launches Nationwide Supply of Locally Made Pralsetinib as China Sales Surge
Premium
Company Announcements
CStone Launches Nationwide Supply of Locally Made Pralsetinib as China Sales Surge
3M ago
2616
CStone Pharmaceuticals Raises Over HK$1 Billion in Completed Share Placement
PremiumCompany Announcements
CStone Pharmaceuticals Raises Over HK$1 Billion in Completed Share Placement
4M ago
2616
CStone to Showcase Promising CS2009 Cancer Data Ahead of Global Phase III Push
PremiumCompany Announcements
CStone to Showcase Promising CS2009 Cancer Data Ahead of Global Phase III Push
4M ago
2616
CStone Showcases Three Novel ADC Candidates, Highlighting EGFR/HER3 Bispecific CS5007
PremiumCompany Announcements
CStone Showcases Three Novel ADC Candidates, Highlighting EGFR/HER3 Bispecific CS5007
4M ago
2616
CStone Pharmaceuticals to Raise About HK$1.05 Billion via Discounted Share Placement
PremiumCompany Announcements
CStone Pharmaceuticals to Raise About HK$1.05 Billion via Discounted Share Placement
4M ago
2616
CStone’s 2025 Loss Widens as R&D Spend Climbs Ahead of Pralsetinib NRDL Boost
PremiumCompany AnnouncementsCStone’s 2025 Loss Widens as R&D Spend Climbs Ahead of Pralsetinib NRDL Boost
5M ago
2616
CStone Fast-Tracks Global Phase III Plan After Strong Early Data for Trispecific Cancer Antibody CS2009
Premium
Company Announcements
CStone Fast-Tracks Global Phase III Plan After Strong Early Data for Trispecific Cancer Antibody CS2009
5M ago
2616
CStone’s Sugemalimab Wins Top ESMO Backing for Stage III Lung Cancer
Premium
Company Announcements
CStone’s Sugemalimab Wins Top ESMO Backing for Stage III Lung Cancer
5M ago
2616

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >